Validating biomarkers amelia and will sytycd dating

10-Oct-2016 09:42

A portfolio of Molecular Methods for validating biomarkers and drug targets Once identified, biomarkers and potential drug targets need to be validated, e.g.

to confirm the efficiency of a given drug candidate against its target or to confirm the differential expression of a given biomarker to report a specific disease condition or a cellular state.

Because of normal clinical or biological variability, candidate biomarkers identified in the discovery stage need to be validated across a large number of samples.

The verification stage requires a high throughput workflow with a minimum of sample preparation that provides both high specificity and sensitivity.

Additionally, the verification stage can confirm that a particular methodology is suitable to be used in the validation phase.

In general, biomarker research follows a continuum that begins with discovery and proceeds through validation to the eventual implementation of biomarkers in a clinical setting.

Biomarker discovery requires high confidence identification of biomarker candidates with simultaneous quantitation information to indicate which proteins are changing to a statistically relevant degree in response to disease.

Biomarker candidates identified in discovery need to be validated using larger sample sets covering a broad section of patient cohorts.

To avoid a potential bottleneck associated with taking a large number of candidates to validation, a verification step is employed to screen potential biomarkers to ensure that only the highest quality leads from the discovery phase are taken into the costly validation stage.

To address this challenge, quantitative proteomics workflows involving SILAC (Stable Isotope Labeling of Amino Acids in Culture) are employed.

In general, biomarker research follows a continuum that begins with discovery and proceeds through validation to the eventual implementation of biomarkers in a clinical setting.

Biomarker discovery requires high confidence identification of biomarker candidates with simultaneous quantitation information to indicate which proteins are changing to a statistically relevant degree in response to disease.

Biomarker candidates identified in discovery need to be validated using larger sample sets covering a broad section of patient cohorts.

To avoid a potential bottleneck associated with taking a large number of candidates to validation, a verification step is employed to screen potential biomarkers to ensure that only the highest quality leads from the discovery phase are taken into the costly validation stage.

To address this challenge, quantitative proteomics workflows involving SILAC (Stable Isotope Labeling of Amino Acids in Culture) are employed.

In the core facility, chiefly the Thermo Orbitrap Elite and Thermo LTQ Orbitrap Velos LC/MS systems are used for biomarker discovery.